{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:23:23Z","timestamp":1788819803051,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome\u2013positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common \u201cgatekeeper\u201d mutation T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-resistant Ph+ leukemia. By inhibiting the BCR-ABL1 kinase, crizotinib efficiently suppressed growth of Ph+ cells without affecting growth of Ph\u2212 cells. It was also active in Ph+ patient-derived long-term cultures (PD-LTCs) independently of the responsiveness\/resistance to other TKIs. The efficacy of crizotinib was confirmed in vivo in syngeneic mouse models of BCR-ABL1- or BCR-ABL1<jats:sup>T315I<\/jats:sup>-driven chronic myeloid leukemia\u2013like disease and in BCR-ABL1-driven acute lymphoblastic leukemia (ALL). Although crizotinib binds to the ATP-binding site, it also allosterically affected the myristol binding pocket, the binding site of GNF2 and asciminib (former ABL001). Therefore, crizotinib has a seemingly unique double mechanism of action, on the ATP-binding site and on the myristoylation binding pocket. These findings strongly suggest the clinical evaluation of crizotinib for the treatment of advanced and therapy-resistant Ph+ leukemia.<\/jats:p>","DOI":"10.1007\/s00277-020-04357-z","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T06:04:40Z","timestamp":1623305080000},"page":"2023-2029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K"],"prefix":"10.1007","volume":"100","author":[{"given":"Afsar Ali","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Haberbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem","family":"Khamaisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Agbarya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Pietsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeh","family":"Eshel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dally","family":"Najib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Chiriches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Gerhard","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Hantschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo M.","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1021-3811","authenticated-orcid":false,"given":"Martin","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"4357_CR1","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3324\/haematol.2015.139337","volume":"101","author":"TI Mughal","year":"2016","unstructured":"Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ (2016) Chronic myeloid leukemia: reminiscences and dreams. Haematologica 101:541\u2013558. https:\/\/doi.org\/10.3324\/haematol.2015.139337","journal-title":"Haematologica"},{"key":"4357_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O\u2019Brien SG, Druker BJ, IRIS Investigators (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917\u2013927. https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"4357_CR3","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/leu.2012.324","volume":"27","author":"OG Ottmann","year":"2013","unstructured":"Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A, Kim DW, Fan X, Novick S, Giles FJ (2013) Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 27:1411\u20131413. https:\/\/doi.org\/10.1038\/leu.2012.324","journal-title":"Leukemia"},{"key":"4357_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-019-0729-2","volume":"12","author":"S Soverini","year":"2019","unstructured":"Soverini S, Bassan R, Lion T (2019) Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol 12:39. https:\/\/doi.org\/10.1186\/s13045-019-0729-2","journal-title":"J Hematol Oncol"},{"key":"4357_CR5","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 117:2562\u20132569. https:\/\/doi.org\/10.1172\/JCI30890","journal-title":"J Clin Invest"},{"key":"4357_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, M\u00fcller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM (2018) Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132:393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"4357_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-019-0468-y","volume":"33","author":"AA Mian","year":"2019","unstructured":"Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG, Hantschel O (2019) The phosphatase UBASH3B\/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis. Leukemia 33:1\u20135. https:\/\/doi.org\/10.1038\/s41375-019-0468-y","journal-title":"Leukemia"},{"key":"4357_CR8","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.1021\/jm2007613","volume":"54","author":"JJ Cui","year":"2011","unstructured":"Cui JJ, Tran-Dub\u00e9 M, Shen H et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal\u2013epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342\u20136363. https:\/\/doi.org\/10.1021\/jm2007613","journal-title":"J Med Chem"},{"key":"4357_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/leu.2014.326","volume":"29","author":"AA Mian","year":"2015","unstructured":"Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M (2015) PF-114, a potent and selective inhibitor of native and mutated BCR\/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. Leukemia 29:1104\u20131114. https:\/\/doi.org\/10.1038\/leu.2014.326","journal-title":"Leukemia"},{"key":"4357_CR10","doi-asserted-by":"publisher","first-page":"e80070","DOI":"10.1371\/journal.pone.0080070","volume":"8","author":"S Badura","year":"2013","unstructured":"Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG (2013) Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in acute lymphoblastic leukemia. PLoS One 8:e80070. https:\/\/doi.org\/10.1371\/journal.pone.0080070","journal-title":"PLoS One"},{"key":"4357_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1021\/acsmedchemlett.7b00084","volume":"8","author":"L Skora","year":"2017","unstructured":"Skora L, Jahnke W (2017) 19 F-NMR-based dual-site reporter assay for the discovery and distinction of catalytic and allosteric kinase inhibitors. ACS Med Chem Lett 8:632\u2013635. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00084","journal-title":"ACS Med Chem Lett"},{"key":"4357_CR12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G (2003) A myristoyl\/phosphotyrosine switch regulates c-Abl. Cell 112:845\u2013857. https:\/\/doi.org\/10.1016\/S0092-8674(03)00191-0","journal-title":"Cell"},{"key":"4357_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.chembiol.2016.06.017","volume":"23","author":"JO Schulze","year":"2016","unstructured":"Schulze JO, Saladino G, Busschots K, Neimanis S, S\u00fc\u00df E, Odadzic D, Zeuzem S, Hindie V, Herbrand AK, Lisa MN, Alzari PM, Gervasio FL, Biondi RM (2016) Bidirectional allosteric communication between the ATP-binding site and the regulatory PIF pocket in PDK1 protein kinase. Cell Chem Biol 23:1193\u20131205. https:\/\/doi.org\/10.1016\/j.chembiol.2016.06.017","journal-title":"Cell Chem Biol"},{"key":"4357_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tibs.2019.09.007","volume":"45","author":"AE Leroux","year":"2020","unstructured":"Leroux AE, Biondi RM (2020) Renaissance of allostery to disrupt protein kinase interactions. Trends Biochem Sci 45:27\u201341. https:\/\/doi.org\/10.1016\/j.tibs.2019.09.007","journal-title":"Trends Biochem Sci"},{"key":"4357_CR15","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1158\/1535-7163.MCT-07-0365","volume":"6","author":"JG Christensen","year":"2007","unstructured":"Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314\u20133322. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0365","journal-title":"Mol Cancer Ther"},{"key":"4357_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/J.CCR.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hern\u00e1ndez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O\u2019Hare T (2014) BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 26:428\u2013442. https:\/\/doi.org\/10.1016\/J.CCR.2014.07.006","journal-title":"Cancer Cell"},{"key":"4357_CR17","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.1038\/ncomms6470","volume":"5","author":"AJ Lamontanara","year":"2014","unstructured":"Lamontanara AJ, Georgeon S, Tria G, Svergun DI, Hantschel O (2014) The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility. Nat Commun 5:5470. https:\/\/doi.org\/10.1038\/ncomms6470","journal-title":"Nat Commun"},{"key":"4357_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","volume":"37","author":"BA Nijmeijer","year":"2009","unstructured":"Nijmeijer BA, Szuhai K, Goselink HM, van Schie MLJ, van der Burg M, de Jong D, Marijt EW, Ottmann OG, Willemze R, Falkenburg JHF (2009) Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol 37:376\u2013385. https:\/\/doi.org\/10.1016\/j.exphem.2008.11.002","journal-title":"Exp Hematol"},{"key":"4357_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3324\/haematol.2011.047191","volume":"97","author":"AA Mian","year":"2012","unstructured":"Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M (2012) p185BCR\/ABL has a lower sensitivity than p210BCR\/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica 97:251\u2013257. https:\/\/doi.org\/10.3324\/haematol.2011.047191","journal-title":"Haematologica"},{"key":"4357_CR20","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/leu.2009.69","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Sch\u00fcll M, Zhao Z, Oancea C, Hundertmark A, Beissert T, Ottmann OG, Ruthardt M (2009) The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL. Leukemia 23:1614\u20131621. https:\/\/doi.org\/10.1038\/leu.2009.69","journal-title":"Leukemia"},{"key":"4357_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/ilar.43.4.244","volume":"43","author":"MFW Festing","year":"2002","unstructured":"Festing MFW, Altman DG (2002) Guidelines for the design and statistical analysis of experiments using laboratory animals. ILAR J 43:244\u2013258. https:\/\/doi.org\/10.1093\/ilar.43.4.244","journal-title":"ILAR J"},{"key":"4357_CR22","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F et al (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555\u20131577. https:\/\/doi.org\/10.1038\/sj.bjc.6605642","journal-title":"Br J Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04357-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04357-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04357-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T05:10:38Z","timestamp":1626412238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04357-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4357"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04357-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"19 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Hantschel reports receiving consulting fees from Intima Biosciences Inc. Dr. Ottmann reports receiving honoraria for AdBoards from Pfizer, Novartis, Celgene, Amgen, Incyte, Takeda, Roche, Fusion Pharma, and Sun Pharma. His research is supported by Incyte, Amgen, and Celgene. Dr. Ruthardt reports having received honoraria from Novartis, Fusion Pharma, and Sun Pharma and his research was supported by Fusion Pharma and Sun Pharma.All other authors declare to have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed and were approved by the relevant monitoring institution (Regierungspr\u00e4sidium Darmstadt - F 39\/08).This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}